Back grey_arrow_rt.gif
 
Archived NATAP Articles from December 2001
 
null.gif
 
 
  1. Structural normalization of the lymphoid tissue asymptomatic HIV-infected patients after 48 weeks potent antiretroviral therapy
    (12/28/01)

  2.  
  3. Transmission of zidovudine resistant strains of HIV-1: the first wave Written by Sally Blower
    (12/27/01)

  4.  
  5. Sexual and drug risk-related behaviours after initiating highly active antiretroviral therapy among injection drug users
    (12/27/01)

  6.  
  7. The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women
    (12/27/01)

  8.  
  9. Long-term efficacy of combination therapy with interferon-2b and ribavirin for severe chronic hepatitis C in HIV-infected patients
    (12/27/01)

  10.  
  11. Acute HIV infection: impact on the spread of HIV and transmission of drug resistance
    (12/27/01)

  12.  
  13. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load
    (12/27/01)

  14.  
  15. High prevalence of HIV infection among youth in a South African mining town is associated with HSV-2 seropositivity and sexual behaviour
    (12/27/01)

  16.  
  17. Increased STDs & HIV Transmission; HCV/HIV Coinfection ../IDSA San Francisco, CA(12/27/01)

  18.  
  19. New HIV drugs, resistance, pharmacogenomicsWritten by Mike Youle, Director of HIV at Royal Free Hospital, UK, London (12/27/01)

  20.  
  21. Drug Interactions and Pharmacokinetics of AntiretroviralsStephen Piscitelli, Pharm.D. Associate Director, Clinical Pharmacology Tibotec-Virco(12/27/01)

  22.  
  23. Safety and Efficacy of Tipranavir (TPV), a Novel Non-Peptide Protease Inhibitor Written by Jules Levin (12/27/01)

  24.  
  25. Anitiretroviral Agents: adherence, PKWritten by Scott Penzak, PharmD, National Institutes of Health (12/27/01)

  26.  
  27. Pharmacokinetic Issues of AntiretroviralsWritten by Stephen Piscitelli, Pharm.D. Associate Director, Clinical Pharmacology Tibotec-Virco (12/27/01)

  28.  
  29. Antiretroviral Therapy: Part 2.- FTC, Interferon, TMC-114 (new PI) Reported for NATAP by Grame Moyle, MD, Ass. Dir. of HIV Research at Chelsea & Westminster Hospital, UK, London(12/27/01)

  30.  
  31. Kaletra and Amprenavir Interaction Two Reports: Impact of ABT 378/r (Kaletra) on the amprenavir (APV) plasma concentrations in HIV-experienced patients treated by the association APV-ABT 378/r by Scott Penzak, PharmD, NIH - and- APV + Kaletra: Is there an interaction here? by Written by Steve Piscatelli, PharmD, Tibotec-Virco (12/27/01)

  32.  
  33. ddI-Tenofovir interaction; ddI-Ribavirin-Interferon interaction; 3TC-ribavirin interaction; elevated glucose & diabetes in HCV/HIV coinfected patients Written for NATAP by Stephen Piscitelli, Pharm.D., Associate Director, Clinical Pharmacology, Tibotec-Virco and Jules Levin, NATAP (12/27/01)

  34.  
  35. The Prevalence of Antiretroviral Drug Resistance in the US(12/27/01)

  36.  
  37. Psychological Aspects of Living with HIV Disease
    (12/21/01)

  38.  
  39. Antiviral PK and Drug-Drug Interactions, Report #1 Reported for NATAP by Scott Penzak, PhD, National Institutes of Health (NIH)    
    (../ICAAC) Chicago,Illinois

    (12/21/01)

  40.  
  41. NATAP ../ICAAC 2001 Antiretroviral therapy, Part 1 Dr Graeme Moyle, Chelsea and Westminster Hospital, London, UK.    
    (../ICAAC) Chicago,Illinois

    (12/21/01)

  42.  
  43. Solid Organ Transplantation in Patients with Human Immunodeficiency Syndrome: a Successful Case Series.    
    (../ICAAC) Chicago,Illinois

    (12/21/01)

  44.  
  45. TMC125 is a Highly Potent Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) in Antiretroviral Therapy (ART)-Naive, HIV-1 Infected Subjects   
    (../ICAAC) Chicago,Illinois

    (12/21/01)

  46.  
  47. Tenofovir 24 week Interim Analysis Phase III Trial in Treatment-Experienced Patients    
    (../ICAAC) Chicago,Illinois

    (12/19/01)

  48.  
  49. BMS-008 Comparative Results of Atazanavir vs Nelfinavir in Combination With d4T (Stavudine) and 3TC (Lamivudine) in treatment-Naive, HIV-Infected Patients    
    (../ICAAC) Chicago,Illinois

    (12/19/01)

  50.  
  51. Once-Daily Atazanavir plus Saquinavir Favorably Affects Total Cholesterol and Fasting Triglycerides in patients Failing Prior PI Therapy Study BMS-009, week 24)    
    (../ICAAC) Chicago,Illinois

    (12/19/01)

  52.  
  53. Fat Loss: efavirenz + AZT/3TC vs indinavir AZT/3TC in study 006 - (12/17/01)

  54.  
  55. Is the Natural History of Hepatitis C Virus Carriers With Normal Aminotransferase Really Benign?    (12/17/01)

  56.  
  57. Amprenavir (APV) Plasma and Intracellular Concentrations When Co-Administered with Ritonavir (RTV) in Twice and Once Daily Regimens in HIV-Infected Patients    
    (../ICAAC) Chicago,Illinois

    (12/17/01)

  58.  
  59. Evaluation of Two doses of Peginterferon Alfa-2a (40KD) (Pegasys) for the Treatment of Chronic Hepatitis C    
    (../ICAAC) Chicago,Illinois

    (12/17/01)

  60.  
  61. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: A long-term retrospective cohort study  PDF  (12/10/01)

  62.  
  63. FIBROSIS (F) AND HISTOLOGICAL ACTIVITY INDEX (HAI) IMPROVE SPONTANEOUSLY IN UNTREATED, NONCIRRHOTIC, PERSISTENTLY VIREMIC IRISH WOMEN WITH CHRONIC HEPATITIS C.    
    (AASLD) Dallas, Texas

    (12/4/01)

  64.  
  65. PREDICTIVE VARIABLES OF HCV-RELATED DISEASE PROGRESSION: NEGATIVE EFFECT OF OVERWEIGHT: diabetes, ALT >60, and weight can have an effect on HCV progression    
    (AASLD) Dallas, Texas

    (12/4/01)

  66.  
  67. INFLUENCE OF STEATOSIS ON CHRONIC HEPATITIS C OUTCOME: PROSPECTIVE STUDY OF 164 PATIENTS WITH CIRRHOSIS    
    (AASLD) Dallas, Texas

    (12/4/01)

  68.  
  69. TIMING THE ANCESTRY OF HEPATITIS C VIRUS GENOTYPE 1A STRAINS IN THE UNITED STATES: the number of mutations don't seem to be associated with disease progression    
    (AASLD) Dallas, Texas

    (12/4/01)

  70.  
  71. One A Day Regimen for HIV: pilot study of FTC, ddI, efavirenz (ECCATHI), Athens, Greece
    (12/3/01)

  72.  
  73. IMPACT OF PREGNANCIES, ORAL CONTRACEPTION AND MENOPAUSE ON LIVER FIBROSIS PROGRESSION IN WOMEN WITH CHRONIC HEPATITIS C    
    (AASLD) Dallas, Texas

    (12/3/01)

  74.  
  75. CLINICAL IMPLICATIONS OF A NEW TRI-PHASIC MODEL FOR HEPATITIS C VIRAL KINETICS DURING IFN-a THERAPY    
    (AASLD) Dallas, Texas

    (12/3/01)

  76.  
  77. LIPID ABNORMALITIES AND CARDIOVASCULAR RISK Written for NATAP by Michael Dube, MD, University of Indiana and the ACTG   - Report - (../../lipodystrophy Conf) Athens, Greece
    (12/03/01)

  78.